BR112022014884A2 - Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave - Google Patents

Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave

Info

Publication number
BR112022014884A2
BR112022014884A2 BR112022014884A BR112022014884A BR112022014884A2 BR 112022014884 A2 BR112022014884 A2 BR 112022014884A2 BR 112022014884 A BR112022014884 A BR 112022014884A BR 112022014884 A BR112022014884 A BR 112022014884A BR 112022014884 A2 BR112022014884 A2 BR 112022014884A2
Authority
BR
Brazil
Prior art keywords
modified vaccinia
vaccinia ankara
recombinant modified
infection
preventing
Prior art date
Application number
BR112022014884A
Other languages
English (en)
Inventor
Jo Hauser Mary
Domi Arban
Guirakhoo Farshad
Original Assignee
Geovax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geovax Inc filed Critical Geovax Inc
Publication of BR112022014884A2 publication Critical patent/BR112022014884A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8636—Vaccina virus vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

VETOR VIRAL DE VACCINIA ANKARA MODIFICADO RECOMBINANTE, VACCINIA ANKARA MODIFICADO RECOMBINANTE, E, MÉTODO PARA REDUZIR OU PREVENIR UMA INFECÇÃO POR CORONAVÍRUS 2 DA SÍNDROME RESPIRATÓRIA AGUDA GRAVE. São providos neste documento vetores virais de vaccinia ankara modificado (rMVA) recombinante compreendendo inserções de ácido nucleico heterólogas que codificam uma ou mais proteínas de SARS-CoV2, peptídeos ou fragmentos do mesmo, operacionalmente ligados a um promotor compatível com sistemas de expressão de poxvírus que, mediante expressão, são capazes de induzir imunidade protetora. As composições podem ser usadas em uma estratégia de vacinação de dose primária ou em uma estratégia de vacinação em duas doses para prover imunidade contra o SARS-CoV2 e variantes do mesmo.
BR112022014884A 2020-02-14 2021-02-12 Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave BR112022014884A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062976913P 2020-02-14 2020-02-14
US202062977402P 2020-02-16 2020-02-16
US202062992710P 2020-03-20 2020-03-20
US202063026580P 2020-05-18 2020-05-18
PCT/US2021/018033 WO2021163622A1 (en) 2020-02-14 2021-02-12 Vaccines and uses thereof to induce an immune response to sars-cov2

Publications (1)

Publication Number Publication Date
BR112022014884A2 true BR112022014884A2 (pt) 2022-10-11

Family

ID=77292751

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014884A BR112022014884A2 (pt) 2020-02-14 2021-02-12 Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave

Country Status (12)

Country Link
US (1) US20220396810A1 (pt)
EP (1) EP4103231A4 (pt)
JP (1) JP2023513611A (pt)
KR (1) KR20220154114A (pt)
CN (1) CN115529817A (pt)
AU (1) AU2021220991A1 (pt)
BR (1) BR112022014884A2 (pt)
CA (1) CA3167052A1 (pt)
IL (1) IL295482A (pt)
MX (1) MX2022009962A (pt)
TW (1) TW202140794A (pt)
WO (1) WO2021163622A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
MX2022015489A (es) * 2020-06-10 2023-03-22 Bavarian Nordic As Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
WO2022025298A1 (ja) * 2020-07-31 2022-02-03 公益財団法人東京都医学総合研究所 組換えワクシニアウイルス
CA3205569A1 (en) 2020-12-22 2022-06-30 CureVac SE Rna vaccine against sars-cov-2 variants
WO2023020939A1 (en) * 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
KR20230031756A (ko) * 2021-08-27 2023-03-07 한국과학기술원 신종 코로나바이러스 감염증 대응 예방 백신 조성물
CN118176303A (zh) * 2021-10-07 2024-06-11 精密纳米***无限责任公司 Rna疫苗脂质纳米颗粒
WO2023069461A2 (en) * 2021-10-19 2023-04-27 Vaxxinity, Inc. Method for the prevention and treatment of coronavirus disease
WO2023092023A2 (en) * 2021-11-17 2023-05-25 City Of Hope Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19)
WO2023200858A1 (en) * 2022-04-13 2023-10-19 The Trustees Of Columbia University In The City Of New York Inhibitory peptides against coronaviruses
GB2624391A (en) * 2022-11-15 2024-05-22 Univ Cape Town Recombinant LSDV vectored bovine coronavirus antigen constructs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
WO2005047459A2 (en) * 2003-08-04 2005-05-26 University Of Massachusetts Sars nucleic acids, proteins, antibodies, and uses thereof
EP1797173B1 (en) * 2004-10-08 2014-05-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Modulation of replicative fitness by using less frequently used synonymous codons
TWI526539B (zh) * 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
CN116064669A (zh) * 2016-01-08 2023-05-05 吉奥瓦科斯公司 用于产生对肿瘤相关抗原的免疫应答的组合物和方法
EP3402888B1 (en) * 2016-01-12 2020-08-26 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating hbv
US20200030432A1 (en) * 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
US20210260182A1 (en) * 2020-02-26 2021-08-26 Scott J. Goebel RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-CoV-2 VIRUS
US11130787B2 (en) * 2020-06-11 2021-09-28 MBF Therapeutics, Inc. Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods
EP3928789A1 (en) * 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens

Also Published As

Publication number Publication date
EP4103231A4 (en) 2024-03-27
AU2021220991A1 (en) 2022-09-29
WO2021163622A1 (en) 2021-08-19
IL295482A (en) 2022-10-01
TW202140794A (zh) 2021-11-01
JP2023513611A (ja) 2023-03-31
US20220396810A1 (en) 2022-12-15
EP4103231A1 (en) 2022-12-21
KR20220154114A (ko) 2022-11-21
CA3167052A1 (en) 2021-08-19
MX2022009962A (es) 2022-11-09
CN115529817A (zh) 2022-12-27

Similar Documents

Publication Publication Date Title
BR112022014884A2 (pt) Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave
BR112022009895A2 (pt) Construtos de terapia de gene de microdistrofina e usos dos mesmos
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
BR112022015626A2 (pt) Composição e métodos de vacinas de mrna contra infecção de novo coronavírus
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus
BR112022022212A2 (pt) Composições para redução específica de drg de expressão de transgene
BR112022019949A2 (pt) Vacina com base em vetor de poxvírus atenuado para proteção contra covid-19
BR112021026832A2 (pt) Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
CO2020002283A2 (es) Métodos de terapia génica del factor viii (fviii)
BR112022010321A2 (pt) Composições e métodos para tratamento de neuropatia óptica hereditária de leber com proteínas nadh desidrogenase
BR112022017678A2 (pt) Expressão sob demanda de fatores exógenos em linfócitos para tratar hiv
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112023000730A2 (pt) Método para induzir e/ou ativar uma resposta imune, forma de dosagem, kit, vetor, célula hospedeira, partículas do vetor lentiviral pseudotipada e composição imunogênica
BR112018015696A2 (pt) composições e métodos para gerar uma resposta imune para um flavivírus
MX2022012251A (es) Vacuna universal contra la influenza usando arnm modificado con nucleósidos.
MX2020013772A (es) Composiciones y métodos para el tratamiento de la neuropatía óptica hereditaria de leber.
BR112023021654A2 (pt) Vacina contra vírus
BR112022006926A2 (pt) Vetor de vírus oncolítico que codifica o polipeptídeo variante de interleucina 2 (vil-2)
BR112022021374A2 (pt) Constructo de dna, genes da proteína s de sars-cov-2, vetor, peptídeo sinal, composição imunogênica e seu método de preparação e vacina
BR112021026292A2 (pt) Cistationina beta sintase peguilada para terapia enzimática para tratamento de homocistinúria
BR112019003181A2 (pt) composição para aumentar uma resposta imune em animal, método para induzir uma resposta imune protetora em um sujeito, e, uso da composição na preparação de um medicamento.
MX2022015489A (es) Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
BR112022007615A2 (pt) Método para tratar ou prevenir papilomatose respiratória recorrente, e, sequência de nucleotídeo